Treatment of children with homozygous familial hypercholesterolaemia

A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry)

(2018) Meral Kayikcioglu et al.   ATHEROSCLEROSIS

PCSK9 inhibitors in clinical practice: Expectations and reality

(2018) Željko Reiner   ATHEROSCLEROSIS

Managing the challenging homozygous familial hypercholesterolemia patient: Academic insights and practical approaches for a severe dyslipidemia, a National Lipid Association Masters Summit

(2017) G. Kees Hovingh et al.   Journal of Clinical Lipidology

Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations

(2017) Evan A. Stein et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors

(2017) Ivan Pećin et al.   European Journal of Preventive Cardiology

Effects of Liver Transplantation on Lipids and Cardiovascular Disease in Children With Homozygous Familial Hypercholesterolemia

(2016) Mercedes Martinez et al.   AMERICAN JOURNAL OF CARDIOLOGY

Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration

(2016) Antonio J. Vallejo-Vaz et al.   ATHEROSCLEROSIS SUPPLEMENTS

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia

(2016) Frederick J. Raal et al.   Journal of Clinical Lipidology

Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel

(2016) Raul D Santos et al.   Lancet Diabetes & Endocrinology

PCSK9 inhibitors – past, present and future

(2015) Željko Reiner   Expert Opinion on Drug Metabolism & Toxicology

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Management of patients with familial hypercholesterolaemia

(2015) Željko Reiner   Nature Reviews Cardiology

Impact of Early Evidence of Atherosclerotic Changes on Early Treatment in Children With Familial Hypercholesterolemia

(2014) Željko Reiner   CIRCULATION RESEARCH

Mutations in STAP1 Are Associated With Autosomal Dominant Hypercholesterolemia

(2014) Sigrid W. Fouchier et al.   CIRCULATION RESEARCH

Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype–phenotype relationship, and clinical outcome

(2014) Barbara Sjouke et al.   EUROPEAN HEART JOURNAL

Carotid Intima-Media Thickness in Children With Familial Hypercholesterolemia

(2013) Dorothé M. Kusters et al.   CIRCULATION RESEARCH

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

(2013) B. G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk

(2013) Gregory S. Thomas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cohort Profile: The Cardiovascular Risk in Young Finns Study

(2008) O. T Raitakari et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY